<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01103518</url>
  </required_header>
  <id_info>
    <org_study_id>AMI 1-16-08-09</org_study_id>
    <nct_id>NCT01103518</nct_id>
  </id_info>
  <brief_title>Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation</brief_title>
  <official_title>Phase IV Study of the Use of Two Preparations of Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation of Hyper-androgenic Origin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundação Educacional Serra dos Órgãos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundação Educacional Serra dos Órgãos</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase IV, randomized, double-blind, comparative study of the use of two
      preparations of ethinyl estradiol and cyproterone acetate in the treatment of menstrual
      irregularities of hyper-androgenic origin.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">January 2011</completion_date>
  <primary_completion_date type="Anticipated">November 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regular Menstruation</measure>
    <time_frame>Treatment month 3</time_frame>
    <description>Percentage of subjects with regular menstruation at the end of treatment month 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Menstrual flow</measure>
    <time_frame>Treatment months 3</time_frame>
    <description>Percentage of subjects with light, moderate, or heavy menstrual flow at treatment month 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Menstrual colic</measure>
    <time_frame>Treatment month 3</time_frame>
    <description>Percentage of subjects reporting menstrual colic at pretreatment and at treatment month 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global self evaluation scores</measure>
    <time_frame>Treatment month 6</time_frame>
    <description>Percentage of subjects with scores of 9 and 10 on the self evaluation of global condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Willingness to continue treatment</measure>
    <time_frame>Treatment month 6</time_frame>
    <description>Percentage of subjects willing to continue treatment with study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Treatment and follow-up period</time_frame>
    <description>Incidence, duration and severity of adverse events, including laboratory tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Menstrual Flow</measure>
    <time_frame>Treatment month 4</time_frame>
    <description>Percentage of subjects with light, moderate, or heavy menstrual flow at treatment month 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Menstrual Flow</measure>
    <time_frame>Treatment month 5</time_frame>
    <description>Percentage of subjects with light, moderate, or heavy menstrual flow at treatment month 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Menstrual Colic</measure>
    <time_frame>Treatment month 4</time_frame>
    <description>Percentage of subjects reporting menstrual colic at pretreatment and at treatment month 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Menstrual Colic</measure>
    <time_frame>Treatment month 5</time_frame>
    <description>Percentage of subjects reporting menstrual colic at pretreatment and at treatment month 5.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Amenorrhea</condition>
  <condition>Dysmenorrhea</condition>
  <condition>Menstruation Disturbances</condition>
  <condition>Hyperandrogenism</condition>
  <arm_group>
    <arm_group_label>Combination 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ethinyl Estradiol + Cyproterone acetate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ethinyl Estradiol + Cyproterone acetate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethinyl Estradiol + Cyproterone acetate</intervention_name>
    <description>Ethinyl Estradiol (0.035mg) + Cyproterone acetate (2mg), coated tablets. Each treatment cycle consists of one tablet, once per day for 21 days followed by a 7-day rest period. A total of 4 treatment cycles will be completed during the study treatment period.</description>
    <arm_group_label>Combination 1</arm_group_label>
    <arm_group_label>Combination 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subject

          -  Premenopausal subject

          -  18 years or older

          -  Medical history of irregular menses lasting at least 3 months

          -  Signature of informed consent

        Exclusion Criteria:

          -  Pregnancy

          -  Use of hormonal contraceptives within 3 months of screening

          -  Primary bilateral oophorectomy

          -  Chemotherapy and / or radiotherapy within 6 months of screening

          -  Hysterectomy

          -  Myotonic dystrophy

          -  Galactosemia

          -  Galactorrhea

          -  History of tuberculosis or schistosomiasis

          -  Elevated prolactin / other significant laboratory alterations

          -  Diabetes

          -  Premature ovarian deficiency

          -  Sensitivity to any component of the drug formula
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos RB Gama, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundação Educacional Serra dos Órgãos</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos P Nunes, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Fundação Educacional Serra dos Órgãos</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital das Clínicas de Teresópolis</name>
      <address>
        <city>Teresópolis</city>
        <state>Rio de Janeiro</state>
        <zip>25976-016</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2010</study_first_submitted>
  <study_first_submitted_qc>April 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2010</study_first_posted>
  <last_update_submitted>August 5, 2010</last_update_submitted>
  <last_update_submitted_qc>August 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Carlos Romualdo Barboza Gama</name_title>
    <organization>Fundação Educacional Serra dos Órgãos</organization>
  </responsible_party>
  <keyword>Menstrual irregularity</keyword>
  <keyword>Menstruation disturbances</keyword>
  <keyword>Hyperandrogenism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysmenorrhea</mesh_term>
    <mesh_term>Amenorrhea</mesh_term>
    <mesh_term>Hyperandrogenism</mesh_term>
    <mesh_term>Menstruation Disturbances</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Cyproterone</mesh_term>
    <mesh_term>Cyproterone Acetate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

